Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:05:25.627Z.
Calculation as of: 2026-10-06T18:05:25.627Z.
Quote observation: 2026-10-06T17:59:52.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8188a044afb190b383642178377b3b21d317b4c37addc3eac3f31d1e137b7514
PE RATIO
N/A
Seer, Inc.
Market Cap
$121.78M
PE Ratio
N/A
| NAME | MARKET CAP | PE RATIO |
|---|---|---|
| Seer, Inc. (SEER) | $121.78M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $120.92M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $123.23M | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $120.09M | N/A |
| Cibus, Inc. (CBUS)vs › | $121.37M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $119.92M | N/A |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $125.06M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $117.50M | N/A |
| BGM Group Ltd. (BGM)vs › | $119.14M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $116.82M | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$2.21
Forward EPS (Est.)
$-1.10
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
